fbpx
SAVE $10 on $100 Orders* • Use code BNR91420

FDA Denies Approval of Ampligen

1 Star2 Stars3 Stars4 Stars5 Stars (26) votes, average: 3.10 out of 5
Loading...

The FDA has informed Hemispherx Biopharma Inc. that research on its experimental drug Ampligen is insufficient to support the drug’s approval for treatment of chronic fatigue syndrome (ME/CFS). The FDA has indicated that at least one more study would be required to credibly demonstrate the drug’s efficacy and safety for treatment of ME/CFS, according to a report featured December 1 by CNNMoney.com and news alerts issued by a number of other pharmaceutical & financial market trackers.

According to the reports, the FDA stipulated a number of requirements that further trials should satisfy, including size, duration, and monitoring criteria. Philadelphia-based Hemispherx has indicated it intends to make a prompt response to the FDA’s suggestions “its top priority.”

For more on Ampligen’s long history of clinical trials, go to http://en.wikipedia.org/wiki/Ampligen

ProHealth CBD Store

 

1 Star2 Stars3 Stars4 Stars5 Stars (26) votes, average: 3.10 out of 5
Loading...



Leave a Reply